Eikon reports Q3 2026 results, ESMO oncology data and new prostate cancer INDNov 12Quarterly updateAkari Therapeutics PlcAtrium Therapeutics
Atrium doses first patient in Corventis trial of ATR 1072 for PRKAG2 syndromeOct 27Trial updateATR-1072Atrium Therapeutics
Atrium Therapeutics clears IND for ATR 1072, activates first Corventis sites for PRKAG2 syndromeAug 13Quarterly updateATR-1072Atrium Therapeutics
Atrium Therapeutics recruiting for Phase 1/2 ATR 1072 trial in PRKAG2 SyndromeJul 31Trial updateATR-1072Atrium Therapeutics